Bex A, et al. - Authors examined 458 cases (mean age 60 years) from July 14, 2010, to March 24, 2016 to estimate if a period of sunitinib therapy before cytoreductive nephrectomy (CN) could improve the consequence as compared to immediate CN followed by sunitinib in subjects with primary metastatic renal cell carcinoma (mRCC). Out of 49, 48 participants were given sunitinib in the deferred CN arm and 40 of 50 in the immediate arm. They noted no improvement in deferred CN as per 28-week progression-free rate (PFR) calculations. They observed that it might help in the identification of cases with inherent resistance and proved informative to patients with primary clear cell mRCC requiring sunitinib in taking treatment decisions.